Drug resistance, illustration of the complexity of translational research. Steiner award lecture 1995

International Journal of Cancer

Volumn 65, Issue 5, 1996, Pages 561-566

  Pinedo, H M ^a,b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DEXAMETHASONE; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MELPHALAN; METHOTREXATE; TUMOR NECROSIS FACTOR; VERAPAMIL; VINCRISTINE;

CANCER CHEMOTHERAPY; CANCER RESEARCH; CLINICAL TRIAL; CONFERENCE PAPER; DRUG RESISTANCE; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; AWARDS AND PRIZES; DRUG RESISTANCE; DRUG RESISTANCE, MULTIPLE; FLUOROURACIL; HUMANS; P-GLYCOPROTEIN; PHARMACOLOGY;

EID: 0029925349     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19960301)65:5<561::AID-IJC1>3.0.CO;2-0     Document Type: Article

References (62)

1. ALBERTS, D.S. and 17 OTHERS, Phase-III study of intraperitoneal cisplatin (CDDP)/intravenous (i.v.) cyclophosphamide (CPA) vs. i.v. CDDP CPA in patients with optimal disease stage-III ovarian cancer: A SWOG-GOG-ECOG mtergroup study (Int. 0051). Proc. ASCO. 14, 760 (1995).
2. CHU, E., KOELLER, D.M., JOHNSTON, P.G , ZINN, S. and ALEGRA, C.J., Regulation of thymidylate synthase in human colon-cancer cells treated with 5-fluorouracil and inierferon-gamma. Mol. Pharmacol., 43, 527-533 (1993).
3. CODACCI-PISANELLI, G., VAN DER WlLT, C.L., PINEDO, H.M., FRANCCHI, F., NOORDUIS, P., VAN LAAR, J.A.M., BRAAKHUIS, B.J.M. and PETERS, G.J., Anti-tumor activity, toxicity and inhibition of thymidylate synthase of prolonged administration of 5-fluorouracil in mice. Europ. J́. Cancer. 31A, 1517-1525 (1995).
4. COIFFIER, B., PHILIP, T., BURNETT, A.K. and SYMANN, M.L., Consensus conference on intensive chemotherapy plus hemapoietic stem-cell transplantation in malignancies. J. clin. Oncol., 12, 226-231 (1994).
5. COLE, S P.C., BHARDWAJ, G., GERLACH, J.H., MACKIE, J.E., GRANT, C.E., ALMQUIST, K.C., STEWART, A.J., KURZ, E.U., DUNCAN, A.M. and DEELEY, R.G., Over-expression of a novel transporter gene in a multidrug-resistant human lung-cancer cell line. Science. 258, 1650-1654 (1992)
6. DE LANGE, J.H.M., SCHIPPER, N.W., SCHUURHUIS, G.J., TEN KATE, T.K., VAN HEUNINGEN, T.H., PINEDO, H.M., LANKELMA, J. and BAAK, J.P., Quantification by laser-scan microscopy of intracellular doxorubicin distribution. Cytometry. 13, 571-576 (1992).
7. EIJDEMS, E.W.H.M., ZAMAN, G.J.R., DE HAAS, M., VERSANTVOORT, C.H M., FLENS, M.J., SCHLPER, R.J., KAMT, E., BORST, P. and BAAS, F., Altered MRP is associated with multidrug resistance and reduced drug accumulation in human SW-1573 cells. Brit. J Cancer, 72, 298-306 (1995).
8. FREI, E., ANIMAN, K., TEICHER, B., EDER, P. and SCHNIPPER, L., Bone-marrow transplantations for solid tumors - Prospects. J. clin. Oncol 7, 515-526 (1989).
9. GALA, J.L., MCLACHLAN, J.M., BELL, D.R., MICHAUX, J.L. and MA, D.D., Specificity and sensitivity of immunocytochemistry for detecting P-glycoprotein in haematological malignancies. J. clin. Pathol. 47, 619-624 (1994).
10. GIANNI, A.M., SIENA, S., BREGM, M , TARELLA, C., STERN, A.C., PILERI, A. and BONADONA, G., Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet, II, 580-585 (1989).
11. GOLDIN, A. and SCRABEL, F.M., Clinical concepts derived from animal chemotherapy studies. Cancer Treat. Rep., 65. 11-19 (1981).
12. HRYNIUK, W. and BUSH, H., The importance of dose intensity in chemotherapy of breast cancer. J. Clin. Oncol., 2, 1281-1288 (1984).
13. IZOUIERDO, M.A. and 12 OTHERS, Drug-resistance-associated marker Lrp for prediction of response to chemotherapy and prognosis in advanced ovarian carcinoma. J. not. Cancer Inst., 87, 1230-1237 (1995).
14. JOHNSTON, P.G., FISHER, E.R., ROCKETIE, H.E., FISHER, B., WOLMARK, N., DRAKE, J.C., CHABNER, B.A. and ALLEGRA, C.J., The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J. clin. Oncol., 12, 2640-2647 (1994).
15. JULIANO, R.L. and LING, V., A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. biophys. Acta. 455, 152-156 (1976).
16. KEIZER, H.J., KARIM, A.B.M.F., NJO, K.H., TIERIE, A.H., SNOW, G.B., VERMORKEN, J.B. and PINEDO, H.M., Feasibility study on daily administration of cis-diamminedichloroplatinum (II) in combination with radiotherapy. Radiother. Oncol., 1, 227-234 (1984).
17. KERR, D.J., DE TAKATS, P.G., FERRY, D.R., BUDDEN, J., BUCKELS, J., NEOPTOLE-MEUS, J., MCARDLE, C.S., LEDERNIAN, J., TAYLOR, I., SEYMOUR, M. and SLEVIN, M., Phase-I clinical trial of hepatic arterial 5-fluorouracil and folinic acid in patients with hepatic metastatic colorectal cancer. Proc. ASCO, 14, 1549 (1995).
18. KOEHNE WOEMPNER, C.H. and 19 OTHERS, Interferon-α does not improve the anti-neoplastic efficacy of high-dose infusional 5-fluorouracil plus folinic acid in colorectal cancer. Ann. Oncol., 6, 461-466 (1995).
19. LEJEUNE, F. and LIÉNARD, D., Value of isolation-perfusion of the limbs in melanomas and sarcomas (editorial). Ann. Chir., 49, 9-12 (1995).
20. LEPELLEY, P., SOENEN, V., PREUDHOMME C., LAI, J.L., COSSON, A. and FENAUX, P., Expression of the multidrug-resistance P-glycoprotein and its relationship to hematological characteristics and response to treatment in myelodysplastic syndromes. Leukemia. 8, 998-1004 (1994).
21. LEYVA, A., NEDERBRAGT, H., LANKELMA, J. and PINEDO, H.M., Methotrexate cytotoxicity: studies on its reversal by folates and nucleosides. Cancer Treat. Rep., 65, 45-50 (1981).
22. LIÉNARD, D., DWALENKO, P., DELMOTTE, J.J., RENARD, N. and LEJEUNE, F.J., High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J. clin. Oncol., 10, 52-60 (1992).
23. Los, G., TUYT, L., VAN VUGT, M., SCHORNAGEL, J. and PINEDO, H.M., Combination treatment of cis- and carboplatin in cancers restricted to the peritoneal cavity in the rat. Cancer Chemother. Pharmacol., 32, 425-433 (1993).
24. LOS, G., VAN VUGT, M.J. and PINEDO, H.M. Response of peritoneal solid tumours after intraperitoneal chemohyperthemia treatment with cisplatin or carboplatin. Brit. J. Cancer, 69, 235-241 (1994).
25. MCGRATH, T. and CENTER, M.S., Mechanisms of multidrug resistance in HL60 cells: evidence that a surface-membrane protein distinct from p-glycoprotein contributes to reduced cellular accumulation of drug. Cancer Res., 48, 3959-3963 (1988).
26. MOLINEUX, G., POJDA, Z., HAMPSON, I.N., LORD, B.I. and DEXTER, T.M., Transplantation potential of peripheral-blood stem cells induced by granulocyte-colony-stimulating factor. Blood. 76, 2153-2158 (1990).
27. MÜLDER, H.S., PINEDO, H.M., TIMMER, A.T., RAO, B.R. and LANKELMA, J., Multidrug-resistance-modifying components in human plasma with potential clinical significance. J. exp. Therap. Oncol. 1, 19-28 (1995)
28. NEDERBRAGT, H., UITENDAAL, M.P., VAN DER GRINT, L., LEYVA, A. and PINEDO, H.M., Reversal of methotrexate inhibition of colony growth of L1210 leukemia cells in semi-solid medium. Cancer Res.. 41, 1193-1198 (1981).
29. PETERS, G.J., VAN DER WILT, C.L. and VAN GROENINGEN, C.J., Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase. Europ. J. Cancer, 30A, 1408-1411 (1994a).
30. PETERS, G.J., VAN DER WILT, C.L., VAN GROENINGEN, C.J., SMID, K., MEIJER, S. and PINEDO, H.M., Thymidylate-synthase inhibition after administration of fluorouracil with or without leucovorin in colon-cancer patients: implications for treatment with fluorouracil. J. clin. Oncol., 12, 2035-2042 (1994b).
31. PETERS, G.J., VAN DIJK, J., LAURENSSE, E.J., VAN GROENINGEN, C.J., LANKELMA, J., LEYVA, A., NADAL, J.C. and PINEDO, H.M. In vitro biochemical and in vivo biological studies of the uridine "rescue" of 5-fluorouracil. Brit. J. Cancer 57, 259-265 (1988).
32. PETERS, G.J. and VAN GROENINGEN, C.J., Clinical relevance of biochemical modulation of 5-fluorouracil. Ann. Oncol. 2, 469-480 (1991).
33. PHILIP, T. and 18 OTHERS, High-dose therapy in autologous bonemarrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's Ivm-phoma. New Engl. J Med., 316,1493-1498 (1987).
34. PINEDO, H.M., Dose-effect relationship in breast cancer. Ann. Oncol., 4, 351-357 (1993).
35. PINEDO, H.M. and CHABNER, B.A., Role of drug concentration, duration of exposure, and endogenous metabolites in determining methotrexate cytotoxicity. Cancer Treat. Rep., 61, 709-715 (1977).
36. PINEDO, H.M., CHABNER, B.A., ZAHARKO, D.S. and BULL, J.M., Evidence for early recruitment of early granulocyte precursors during high-dose methotrexate infusions in mice. Blood, 48, 301-307 (1976a).
37. PINEDO, H.M. and GIACCONE, G., P-glycoprotein as a marker of biological behavior. Editorial New Engl. J. Med. 21, 1417-1419 (1995).
38. PINEDO, H.M., KARIM, A.B.M.F., VAN VLIET, W.H., SNOW, G.B. and VERMORKEN, J.B., Daily cis-dichlorodiammineplatinum (II) as a radio-enhancer: a preliminary toxicity report. J. Cancer Res. clin. Oncol., 105, 79-82 (1983).
39. PINEDO, H.M. and PETERS, G.J., 5-fluorouracil; biochemistry and pharmacology. J. Clin. Oncol., 6, 1653-1664 (1988).
40. PINEDO, H.M., ZAHARKO, D.S., BULL, J.M. and CHABNER, B.A., The reversal of methotrexate cytotoxicity to mouse bone-marrow cells by leuvovorin and nucleosides. Cancer Res., 36, 4418-4424 (1976b).
41. PINEDO, H.M., ZAHARKO, D.S., BULL, J.M. and CHABNER, B.A., The relative contribution of drug concentration and duration of exposure to mouse bone-marrow toxicity during continuous methotrexate infusion. Cancer Res., 37, 445-450 (1977).
42. RADERER, M. and SCHEITHAUER, W., Treatment of advanced colorectal cancer with 5-fluorouracil and interferon-α: an overview of clinical trials. Europ. J. Cancer, 31, 1002-1008 (1995).
43. SCHAAKE-KONING, C. and 15 OTHERS, Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. New Engl. J. Med., 326, 524-530 (1992).
44. SCHABEL, F.M., GRISWOLD, D.P., CORBETT, T.H. and LASTER, W.R., Increasing therapeutic response rates to anti-cancer drugs by applying the basic principles of pharmacology. Pharmacol. Ther., 20, 283-305 (1983).
45. SCHEPER, R.J., BROXTERMAN, H.J., SCHEFFER, G.L., KAAIJK, P., DALTON, W.S., VAN HEIJMNGEN, H.T.H.M., VAN KALKEN, C.K., SLOVAK, M.L., DE VRIES, E.G.E., VAN DER VALK, P., MEIJER, C.J.L.M. and PINEDO, H.M., Over-expression of a M(r) 110,000 vesicular protein in non P-glycoprotein-mediated multidnig resistance. Cancer Res., 53, 1475-1479 (1993).
46. SCHEPER, R.J., BULTE, J.W.M., BRAKKEE, J.G., QUAK, J.J., VAN DER SCHOOT, E., BALM, A.J., MEIJER, C.J., BROXTERMAN, H.J., KUIPER, C.M., LANKELMA, J. and PINEDO, H.M., Monoclonal antibody JSB-1 detects a highly conserved epitope on the P-glycoprotein associated with multidrug resistance. Int. J. Cancer, 42, 389-394 (1988).
47. SCHORNAGEL, J.H., LEYVA, A. and PINEDO, H.M., Is there a role for thymidine in cancer chemotherapy? Cancer Treat. Rev., 9, 331-352 (1982).
48. SCHUURHUIS, G.J., BROXTERMAN, H.J., OSSENKOPPELE, G.J., BAAK, J.P.A., EEKMAN, C.A., KUIPER, C.M., FELLER, N., VAN HEIJNINGEN, T.H.M., KLUMPER, E., PIETERS, R., LANKELMA, J. and PINEDO, H.M., Functional multidrug-resistance phenotype associated with combined over-expression of Pgp/MDR1 and MRP together with cytosinearabinoside sensitivity may predict clinical response in acute myeloid leukemia. Clin. Cancer Res., 1, 81-93 (1995).
49. SHAH, A., HARTSELL, F., GHALIE, R. and KAIZER, H., Patterns of failure following bone-marrow transplantation for metastatic breast cancer: the role of consolidative local therapy. Int. J Rad. Oncol. Biol. Phys., 32, 1433-1438 (1993).
50. THOMAS, E.D., CLIFT, R.A. and BUCKNER, C.D., Marrow transplantation for patients with acute non-lymphoblastic leukemia who achieve a first remission. Cancer Treat. Rep., 66, 1463-1466 (1982).
51. TSURUO, T., Reversal of acquired resistance to vinca alkaloids and anthracycline antibiotics. Cancer Treat. Rep., 67, 889-894 (1983).
52. VAN DER WILT, C.L., PINEDO, H.M., SMID, K. and PETERS, G.J., Elevation of thymidylate synthase following 5-fluorouracil treatment is prevented by the addition of leucovorin in murine colon tumors. Cancer Res.. 52, 4922-4928 (1992).
53. VAN GROENINGEN, C.J., LEYVA, A., KRAAL, I., PETERS, G.J. and PINEDO, H.M., Clinical and pharmacokinetic study of prolonged administration of high-dose uridine intended for rescue from 5-fluorouracil toxicity. Cancer Treat. Rep., 70, 745-750 (1986).
54. VAN GROEMNGEN, C.J., PETERS, G.J., LEYVA, A., LAURENSSE, E.J. and PINEDO, H.M., Reversal of 5-fluorouracil-induced myelosuppression by prolonged administration of high-dose uridine. J. nat. Cancer Inst., 81, 157-162 (1989a).
55. VAN GROENINGEN, C.J., PETERS, G.J., NADAL, J.C., LAURESSE, E. and PINEDO, H.M., Clinical and pharmacological study of orally administered uridine. J nat. Cancer Inst., 83, 437-441 (1991).
56. VAN GROENINGEN, C.J., PETERS, G.J. and PINEDO, H.M., Lack of effectiveness of combined 5-fluorouracil and leucovorin in patients with 5-fluorouracil-resistant advanced colorectal cancer. Europ. J. Cancer clin Oncol., 25, 45-49 (1989b).
57. VAN GROENINGEN, C.J., PETERS, G.J. and PINEDO, H.M., Reversal of 5-fluorouracil-induced toxicity by oral administration of uridine. Ann. Oncol. 4, 317-320 (1993).
58. VAN KALKEN, C.K., BROXTERMAN, H.J., PINEDO, H.M., FELLER, N., DEKKER, H., LANKELMA, J. and GIACCONE, G., Cortisol is transported by the multidrug-resistance gene product P-glycoprotein. Brit. J. Cancer, 67, 284-289 (1993).
59. VERSASTVOORT, C.H.M., BROXTERMAN, H.J., BAGRIJ, T., SCHEPER, R.J. and TWENTYMAN, P.R., Regulation by gluthatione of drug transport to multidrug-resistant human lung-tumour cell lines overexpressing MRP. Brit. J. Cancer, 72, 82-89 (1995).
60. WILSON, W.H., BATES, S.E., FOJO, A., BRYANT, G., ZHAN, Z., REGIS, J.A., WITTES, R.E., JAFFE, E.S., STEINBERG, S.M., HERDT, J. and CHABNER, B.A., Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. J. clin. Oncol., 13, 1995-2004 (1995).
61. WODINSKY, I., SWINIARSKI, J., KENSLER, C.J. and VENDITTI, J.M., Combination radiotherapy and chemotherapy for P3S8 lymphocytic leukemia in vivo. Cancer Chemother. Rep., 4, 73-97 (1974).
62. ZAK, M. and DROBNIK, J., Effects of cis-dichlorodiammine-platinum (II) on the post-irradiation lethality in mice after irradiation with X-rays. Strahlentherapie. 142, 112-115 (1971).